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Purpose: A phase 3 randomized study (COG ANBL0032) demonstrated significantly 
improved outcome by adding immunotherapy with ch14.18 antibody to isotretinoin as 
post-consolidation therapy for high-risk neuroblastoma (NB). This study, ANBL0931, 
was designed to collect FDA-required safety/toxicity data to support FDA registration 
of ch14.18.
Experimental design: Newly diagnosed high-risk NB patients who achieved at least 
a partial response to induction therapy and received myeloablative consolidation with 
stem cell rescue were enrolled to receive six courses of isotretinoin with five concomitant 
cycles of ch14.18 combined with GM-CSF or IL2. Ch14.18 infusion time was 10–20 h 
per dose. Blood was collected for cytokine analysis and its association with toxicities 
and outcome.
results: Of 105 patients enrolled, five patients developed protocol-defined unacceptable 
toxicities. The most common grade ≥ 3 non-hematologic toxicities of immunotherapy for 
cycles 1–5, respectively, were neuropathic pain (41, 28, 22, 31, 24%), hypotension (10, 17, 
4, 14, 8%), allergic reactions (ARs) (3, 10, 5, 7, 2%), capillary leak syndrome (1, 4, 0, 
2, 0%), and fever (21, 59, 6, 32, 5%). The 3-year event-free survival and overall survival 
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were 67.6 ± 4.8% and 79.1 ± 4.2%, respectively. AR during course 1 was associated 
with elevated serum levels of IL-1Ra and IFNγ, while severe hypotension during this 
course was associated with low IL5 and nitrate. Higher pretreatment CXCL9 level was 
associated with poorer event-free survival (EFS).
Conclusion: This study has confirmed the significant, but manageable treatment-related 
toxicities of this immunotherapy and identified possible cytokine biomarkers associated 
with select toxicities and outcome. EFS and OS appear similar to that previously reported 
on ANBL0032.
Keywords: neuroblastoma, immunotherapy, anti-GD2 chimeric antibody, cytokines, safety, cytokine biomarkers
inTrODUCTiOn
Immunotherapy using anti-glycolipid disialoganglioside (GD2) 
antibody combined with cytokines has become the standard 
treatment in North America for patients with high-risk neu-
roblastoma (NB) who have achieved at least a partial remission 
following intensive induction and consolidation (1). Induction 
treatment consists of 5–6 cycles of multiagent chemotherapy 
combined with surgery followed by the consolidation phase that 
includes single or tandem autologus stem cell transplant with 
subsequent radiotherapy. Several anti-GD2 antibodies have 
been tested for clinical use including murine 3F8, chimeric 14.18 
(ch14.18, dinutuximab), humanized 14.18 (hu14.18K322A), 
and humanized 14.18 fused to interleukin-2 (hu14.18-IL2) 
(2–5). Ch14.18 is an anti-GD2 monoclonal antibody, which is a 
chimeric construct composed of the variable region heavy and 
light chain genes of the murine mAb14.G2a and the human con-
stant region genes for heavy chain IgG1 and light chain kappa 
(6). The primary objective of this study was to comprehensively 
define the safety profile of ch14.18 when administered with 
cytokines and isotretinoin in high-risk NB patients after com-
pleting standard induction chemotherapy and autologous stem 
cell transplant (ASCT) and generate data required to support 
the Biological License Application (BLA) for ch14.18 with the 
Food and Drug Administration (FDA).
Cytokine release often occurs during antibody-based immuno-
therapeutics and is commonly associated with infusion reactions 
and other toxicities. Therapeutic IL-2 not only induces immune 
cell stimulation but may also induce hypotension and capillary 
leak syndrome. This is believed to be mediated by nitric oxide 
(NO) directly or indirectly via induction of tumor necrosis 
factor alpha (TNFα) and interferon gamma (IFNγ) or other 
proinflammatory cytokines such as IL-6 (7–9). Cytokine release 
in response to other immunotherapies is common and believed 
to be responsible for associated toxicities (10). Cytokines have 
also been implicated in patient survival, with increased IL-6 
levels at diagnosis associated with poor outcome in numerous 
cancers including NB (10, 11). However, the relationship of 
cytokine levels with outcome from immunotherapy has never 
been investigated. Thus, serum cytokine profiles during ch14.18 
immunotherapy may be able to predict toxicities and/or outcome 
of the immunotherapy and were thus investigated as part of 
this study.
MaTErialS anD METHODS
Patient Population
All NB patients categorized as high-risk at the time of diagnosis, 
and met the International Neuroblastoma Response Criteria 
(INRC) for complete response, very good partial response (PR), 
or PR for primary site, soft tissue, bone metastases at their pre-
ASCT evaluation at study entry were eligible [(12), described 
in online Appendix]. High-risk patients were International 
Neuroblastoma Staging System (INSS) stage 4 greater than 
18 months of age, INSS stage 4 with MYCN amplification, regard-
less of age, INSS stage 4 between ages of 12 and 18 months with 
unfavorable histology and/or diploid tumor DNA content, INSS 
stage 3 with amplified MYCN, regardless of age, INSS stage 3 and 
unfavorable histology greater than 18 months of age, INSS stage 
2 with MYCN amplification regardless of age. In addition, all 
patients must have completed therapy including intensive induc-
tion chemotherapy followed by myeloablative consolidation with 
ASCT and radiotherapy, including enrollment onto contem-
porary clinical trials within the Children’s Oncology Group or 
New Advances in Neuroblastoma Research (regimen specifics 
included in Appendix, online only). No more than 9 months from 
the date of starting the first induction chemotherapy to the date 
of ASCT was allowed. Patients had to be enrolled no later than 
Day 100 after ASCT infusion (or day 100 from second stem cell 
infusion if tandem transplant). Patients had to be enrolled after 
completion of radiotherapy post-ASCT, and after completion of 
tumor assessment post-radiotherapy. There was no age restric-
tion. Patients who had received prior anti-GD2 therapy were 
excluded. Other organ-specific and inclusion/exclusion criteria 
are provided in the Appendix (online only).
Written informed consent was obtained from parents or legal 
guardians. Patients were treated at thirty Children’s Oncology 
Group institutions on a protocol approved by the institution’s 
local Institutional Review Board (IRB) or National Cancer 
Institute (NCI)-sponsored pediatric central institutional review 
board (NCT01041638; see Appendix for the list of institutions, 
online only).
Study Design
All patients received six courses of isotretinoin (ISOT). For 
the first five of these courses, patients also received ch14.18 
AB
C
FiGUrE 1 | Immunotherapy treatment schema. (a) Schedule of overall dinutuximab, GM-CSF, IL2, and 13cisRA. (B) Treatment schema for courses 1, 3, and 5 with 
GM-CSF (28 days per course). (C) Treatment schema for courses 2 and 4 with IL2.
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plus cytokines, with ch14.18 and sargramostim (granulocyte 
macrophage-colony stimulating factor, GM-CSF) administered 
in Courses 1, 3, and 5, and ch14.18 with aldesleukin (IL-2) given 
in Courses 2 and 4 (Figure 1) Ch 14.18 was administered every 
28 days, as described previously (1).
Toxicities were graded according to the Common Termino-
logy Criteria for Adverse Events (version 4.0). Grades 1 through 
5 toxicities were captured. Unacceptable toxicities were defined 
as: Grade ≥ 4 allergic reaction (AR), anaphylaxis, Grade ≥ 4 cap-
illary leak syndrome, Grade ≥ 3 peripheral motor neuropathy 
4Ozkaynak et al. Immunotherapy in NB
Frontiers in Immunology | www.frontiersin.org June 2018 | Volume 9 | Article 1355
with duration ≥ 2 weeks, and Grade ≥ 4 pain, requiring narcotics/ 
lidocaine and persisting ≥  4  days after the end of ch14.18 
infu sion. AR was defined to include bronchospasm, stridor, 
wheezing, urticarial, and anaphylaxis. Special attention was 
placed on toxicities resulting from direct neuronal toxicity or 
from immune/cytokine reactions extrapolated from similar data 
based on ANBL0032 (NCT01418495). Required pretreatment 
and on-study observations were used to monitor toxicity and 
criteria for dose modifications (Appendix, online only). Tumor 
response was reported using INRC.
Drug Supply and administration
Ch14.18 was supplied by the National Cancer Institute and 
administered to hospitalized patients intravenously over a 
minimum of 10 h at 25 mg/m2/day for four consecutive days 
every 28  days. This dose is the equivalent of the currently 
FDA approved dinutuximab dose of 17.5 mg/m2/day. Ch14.18 
infusion was started at 1.25 mg/m2/h for the first 0.5 h, then, 
increased to 2.5  mg/m2/h for the remainder of the dose, if 
tolerated, to be administered over ≥10 h. The maximum infu-
sion time from initiation of ch14.18 was 20 h even if the total 
dose had not been administered in that timeframe. Patients 
were pre-medicated with diphenhydramine or hydroxyzine, 
acetaminophen and recommended to be on intravenous (IV) 
narcotics as a loading dose immediately prior to ch14.18 
administration followed by continuous IV infusion narcotics. 
During courses 1, 3, and 5, commercially available GM-CSF 
was administered either subcutaneously (strongly recom-
mended) or IV over 2 h at 250 µg/m2/day for 14 days. Ch14.18 
was started on the fourth day of GM-CSF injections, 1 h after 
GM-CSF and immediately following a 10  ml/kg IV bolus of 
normal saline each day. During course 2 and 4, commercially 
available aldesleukin (IL-2) at 3 Million International Units/
m2/day was administered by IV continuous infusion for 96 h. 
Seven days later, patients received an additional 4.5 Million 
IU/m2/day of aldesleukin administered by IV continuous 
infusion over 96 h along with simultaneous administration of 
ch14.18. Isotretinoin at 80  mg/m2/dose (2.67  mg/kg/dose if 
weight ≤ 12 kg) was administered by mouth twice daily (BID) 
for 14 days, every 28 days starting on day 11 for course 1, day 
10 for courses 3 and 5, and day 14 for courses 2 and 4. Patients 
received only isotretinoin for course 6 (same dose as in previ-
ous courses) starting 14 days after completion of course 5.
The use of corticosteroids and other immunosuppressive medi-
cations were prohibited, except for life-threatening conditions 
(i.e., life-threatening AR, including anaphylaxis, bronchospasm, 
and stridor) unresponsive to other measures. Other supportive 
care measures are listed in the Appendix (online only).
Pharmacokinetic Studies
Plasma ch14.18 levels were quantified using an electrochemi-
luminescence immunoassay (BioAgilytix, Durham, NC, USA) 
as previously described (13). Samples were obtained before 
starting GM-CSF and after ch14.18 in Courses 1 and 5 and prior 
to IL-2 and after ch14.18 and IL-2 in Course 4. A final sample 
was obtained within 2 weeks after the last dose of isotretinoin in 
Course 6.
Cytokine and nitrate analysis
Heparinized blood and serum samples were collected 
before starting immunotherapy and just before the fourth 
doses of ch14.18 infusion on courses 1 (days −1 and 6) and 
4 (days 80 and 90) and shipped by overnight courier for lab 
analyses. Most analytes were measured using SimplePlex assays 
(ProteinSimple, San Jose, CA, USA) except the following: IL-6 
by the Meso Scale Discovery (MSD, Rockville, MD, USA) IL-6 
assay, IL-1 receptor antagonist (IL-1Ra) by the R&D Systems 
assay (R&D Systems, Minneapolis, MN, USA), and nitrate by 
the R&D Systems Parameter Total Nitric Oxide and Nitrate/
Nitrite Kit.
Human anti-Chimeric antibody  
(HaCa) Studies
A validated MSD electrochemiluminescent assay was used to 
measure HACA (BioAgilytix, Durham, NC, USA). Methodological 
details are included in Appendix (Online only).
Statistical analysis
In accordance with the protocol, analyses were performed as 
intent-to-treat. Toxicity data were summarized using propor-
tions with two-sided 95% Wilson (score) confidence intervals. 
For selected toxicities of interest, the median, minimum, and 
maximum duration were calculated. Protocol monitoring 
rules for unacceptable toxicity (two-stage design) and toxic 
death were applied. McNemar’s test for paired data was used to 
compare the incidence of toxicities between GM-CSF (cycles 
1, 3, and 5) and IL-2 (cycles 2 and 4) containing courses in 
patients with at least one course of each. Event-free survival 
(EFS) and overall survival (OS) curves were generated using 
the methods of Kaplan and Meier, with standard errors per Peto 
et al. (14, 15). For EFS, the time to event was calculated from 
study enrollment until the first occurrence of relapse, progres-
sive disease, secondary malignancy, death, or until last contact 
if no event occurred. For OS, it was time from enrollment until 
death, or until last contact with the patient. Cytokine levels 
during courses were compared by Wilcoxon signed-rank test 
comparison of paired samples: day −1 versus day 6 and day 80 
versus day 90. A p-value of <0.0036 was considered statistically 
significant at level 0.05 after Bonferroni correction for the 14 
cytokine compared at each course. A two-sided Mann–Whitney 
U-test was used to compare analyte levels in patients experienc-
ing a vascular toxicity (hypotension or capillary leak) or AR 
(anaphylaxis, urticaria, wheezing, stridor, bronchospasm, and 
generally diagnosed AR) versus no AR and was considered 
statistically significant at p ≤ 0.05.
rESUlTS
Patient Characteristics
One hundred and five patients were enrolled. One patient 
withdrew consent prior to the initiation of therapy, but remains 
included in these intent-to-treat analyses. Ninety-three percent of 
the patients were less than 12 years old. Patient characteristics are 
summarized in Table 1.
TaBlE 2 | Toxicities defined as “Unacceptable” according to COG protocol 
ANBL0931 (n = 105 patients enrolled).
Course number of patients with 
unacceptable toxicities
Description of the  
unacceptable toxicity
Course 1 (n = 104) 2 Grade 4 allergic reaction (AR)/
anaphylaxis (n = 1); grade 5  
cardiac arrest (n = 1)
Course 2 (n = 100) 1 Grade 4 AR
Course 3 (n = 98) 1 Grade 4 AR
Course 4 (n = 90) 1 Grade 4 anaphylaxis
Course 5 (n = 88) 0 None
Course 6 (n = 81) 0 None
TaBlE 1 | Characteristics of patients enrolled on COG ANBL0931 (n = 105).
Age, years
Median 4.1
Range 1.1–27.5
Sex
Male 59 (56.2%)
Female 46 (43.8%)
Race
White 82 (78.1%)
Black 10 (9.5%)
Other 13 (12.4%)
Ethnicity
Hispanic 9 (8.6%)
Other 96 (91.4%)
Histology
Favorable 4 (5.5%)
Unfavorable 69 (94.5%)
Unknown 32
INSS stage
Stage 1a 2 (2.5%)
Stage 2b 1 (1.2%)
Stage 3 15 (18.5%)
Stage 4 63 (77.8%)
Unknown 24
MYCN status
Non-amplified 40 (57.1%)
Amplified 30 (42.9%)
Unknown 35
Number of ASCTs prior to study
One 88 (83.8%)
Two 17 (16.2%)
Disease status at study entry
Complete response 29 (27.6%)
Very good partial response (PR) 36 (34.3%)
PR 40 (38.1%)
aMYCN amplified tumor (n = 1), progression to metastatic disease meeting high-risk 
criteria during follow-up (n = 1).
bMYCN amplified tumor.
TaBlE 3 | Proportion of patients with Grades 1–5 toxicities attributed to ch14.18 on COG study ANBL0931.
Pain (%) allergic reactions (%) Capillary leak syndrome (%) Hypotension (%) Fever (%) Ocular toxicity (%)
Course 1 (n = 104) 93 25 24 60 91 2
Course 2 (n = 100) 78 28 39 64 92 3
Course 3 (n = 98) 79 16 14 58 69 3
Course 4 (n = 90) 77 21 33 69 87 1
Course 5 (n = 88) 70 13 17 52 67 1
Course 6 (n = 81) 26 0 0 14 19 0
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Toxicities
Five patients developed protocol-defined unacceptable toxici-
ties and came off study: four Grade 4 AR and one sudden death 
(Table 2). The pre-specified monitoring rule for too many unac-
ceptable toxicities was not met. Sudden death occurred in one 
patient who had been clinically stable while awaiting start of 
course 2 of immunotherapy. The patient experienced sudden onset 
of abdominal pain and subsequent cardiac arrest and unable to 
be resuscitated by paramedics. No autopsy was performed. Three 
more patients discontinued the study as per parents/physician 
choice secondary to immunotherapy-related toxicities.
The proportion of patients experiencing clinically relevant 
toxicities, all grades, across all cycles of therapy are summarized 
in Table  3 (Grade 1 and 2 toxicities provided in Table S1 in 
Supplementary Material). The most common Grade 3 or higher 
non-hematologic toxicities of immunotherapy were neuropathic 
pain and fever, followed by, hypotension, AR, and capillary leak 
syndrome (Table 4). Of the 104 patients who received course 1, 
103 (99%) experienced at least one Grade 3 or greater toxicity 
(data not shown). Pain occurred more frequently during Course 
1, then, at lower rates thereafter (Tables  3 and 4). There was 
not a statistically significant difference for AR, capillary leak 
syndrome and hypotension between GM-CSF vs IL-2 courses. 
Although not statistically significant, capillary leak syndrome 
and grades 3–4 hypotension occurred at higher rates during the 
IL-2 courses. The median duration of select adverse events is 
presented in Table  5. Most toxicities resolved within 3  days 
with the exception of the rare ocular and hypertension toxicity 
(Table 5). Dose reduction of ch14.18 was reported in 45 patients 
(43.27%), i.e., these patients received less than 90% of the intended 
dose at some point during courses 1–5. Of the 45 patients with 
dose reductions, ARs, capillary leak, and hypotension were the 
main indications. Of the 104 patients who received treatment 
79 patients received ≥ 90%, 8 patients ≥ 80 to <90%, 9 patients 
≥70 to <80%, 1 patient ≥ 60 to <70%, 3 patients ≥ 50 to <60%, 
and 4 patients received <50% of the cumulative intended dose of 
ch14.18. The use of morphine, fentanyl, meperidine, hydromor-
phone, and ketamine were reported in 100 patients at some point 
during the study. In 20 of the 104 patients (19.2%), GM-CSF was 
administered intravenously instead of subcutaneously.
Pharmacokinetics
The mean ch14.18 concentration appeared to be similar during 
the peak of the three courses studied (first, third, and fourth), 
with mean concentrations of 5,965, 4,650, and 5,907  ng/ml, 
respectively (Table 6). Ch14.18 was still detectable at its trough 
TaBlE 6 | Summary of dilution corrected mean of ch14.18 concentration values 
(ng/mL).
Study day N (patients) Mean SD Median Min, max
6 (peak) 80 5,965 2,463 5.761 1,233, 13,380
80 (trough) 78 844 1,598 341 6, 10,910
90 (peak) 71 4,650 2,263 4,506 34, 9,611
111 (trough) 66 730 1,468 362 8, 11,630
118 (peak) 63 5,907 2,550 5,844 77, 15,630
Completion of 
study (trough)
66 178 188 126 1, 890
TaBlE 5 | Median duration (in days) of select adverse events within the subset of patients who experienced those eventsa.
Courses 1, 3, or 5  
(with GM-CSF) (n = 104)
Courses 2 or 4  
(with il-2) (n = 100)
anytime on treatment
Toxicities N with toxicity Median duration (days) N with toxicity Median duration (days) N with toxicity Median duration (days)
Neuropathic pain 54 2.0 38 2.0 64 2.5
Ocular toxicitiescb 14 3.5 6 69.0 19 5.0
Anatomical paind 54 2.0 39 2.0 64 3.0
Capillary leak syndrome 1 2.0 6 2.5 7 2.0
Allergic reaction 8 1.5 13 2.0 17 2.0
Hypertension 1 238.0 2 7.0 3 13.0
Fever 28 1.0 63 2.0 70 2.0
aFor a given adverse event, the longest duration of an event was selected per patient per treatment course. Only Grades 3–4 were used in calculations unless otherwise specified 
(the Grade 5 cardiac arrest has been excluded from this table).
bOne ocular toxicity was ongoing and had no date of resolution. This record is omitted from calculations.
cAll grades were used for calculations.
dSee Table S1 in Supplementary Material for the description of anatomical pain.
TaBlE 4 | Proportion of patients (95% confidence interval) with clinically significant Grade 3 and 4 toxicities attributed to ch14.18 on COG study ANBL0931 (courses 1, 
3, and 5 contained GM-CSF and Courses 2 and 4 contained IL-2).
Pain allergic reactions Capillary leak syndrome Hypotension Fever
Course 1 (n = 104) 41% (32.4, 51.0%) 3% (0.9, 8.1%) 1% (0.2, 5.2%) 10% (5.3, 16.8%) 21% (14.4, 30.0%)
Course 2 (n = 100) 28% (20.1, 37.5%) 10% (5.5, 17.4%) 4% (1.6, 9.8%) 17% (10.9, 25.6%) 59% (49.2, 68.1%)
Course 3 (n = 98) 22% (15.3, 31.7%) 5% (2.2, 11.4%) 0% (0.0, 3.8%) 4% (1.6, 10.0%) 6% (2.8, 12.7%)
Course 4 (n = 90) 31% (22.5, 41.3%) 7% (3.1, 13.8%) 2% (0.6, 7.7%) 14% (8.6, 23.2%) 32% (23.5, 42.4%)
Course 5 (n = 88) 24% (16.2, 33.7%) 2% (0.6, 7.9%) 0% (0.0, 4.2%) 8% (3.9, 15.5%) 5% (1.8, 11.1%)
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time points, just prior to starting the third and fourth courses, 
with mean concentrations of 844 and 730 ng/ml, respectively.
HaCa response
A total of 533 samples were analyzed for HACA from 103 
patients. Eight patients had a confirmed positive HACA response. 
All HACA positivity was detected during and after course 3. 
No dose modification was done based on HACA development.
Cytokine Profiles and association  
With ars
After correcting for multiple comparisons, the average levels of 
9 of 13 cytokines on course 1, and 11 of 13 on course 4 were 
significantly elevated with respect to the pre-treatment values 
(Figure 2A; Table S2 in Supplementary Material). IL-5 exhibited 
the most dramatic rise during immunotherapy. On the other 
hand, IL-4 and IL-18 on course 1 and IL12p70 and IL-8 on both 
courses did not change significantly during treatment.
The average cytokine levels of patients with AR were indis-
tinguishable from the overall population, with no significant 
differences in the levels of the cytokines between the “non-AR” 
versus the “any AR” population of patients, except for course 1 
(day 6) IL-1Ra (2,043.6 vs 2,522.3 pg/ml, p = 0.02) and IFNγ (35.9 
vs 73.8 pg/ml, p = 0.02), though neither was significant at course 
4 (day 90) (Figure  2B; Table S2 in Supplementary Material). 
Similarly, when levels for each of the cytokines were compared 
for patients with no or Grade 1 AR versus patients with Grade ≥ 2 
AR, no associations were identified (data not shown). At each 
time point, we then investigated the 14 individual patients with 
the highest level of each of the 14 cytokines. At day 6, the patients 
with “extreme” cytokine levels were as likely to be associated with 
the non-AR group as with the AR group (7 of 14 cytokines in 
each group). At day 90, only 3 of the patients with the extreme 
cytokine value had an AR; the patients with the highest levels of 
IL-10 and IL-17A experienced grade 1 toxicities (urticaria and 
AR, respectively), while the patient with the highest levels of 
CXCL9 experienced grade 3 urticaria. It should be pointed out 
that any toxicity that occurred between the start of a given course 
and before the fourth dose of ch14.18 (day 6 for course 1 or day 
90 for course 4), when blood was drawn, were considered for 
correlations with cytokine levels.
Among the patients with anaphylaxis, a blood sample was 
available from only one patient (during Course 4, Figure 2B; 
Table S2 in Supplementary Material) taken the day prior to the 
documentation of anaphylaxis. Most of the cytokines levels on 
day 90 in this patient were ≤2-fold different from the average 
levels of all course 4 AR patients. One exception was IL-17A, 
a cytokine known to be associated with food allergy (16). The 
FiGUrE 2 | Continued
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IL-17A levels in this patient (4.02 ± 0.14) were higher than 29 
of 32 (91%) patients who did not have any AR. Furthermore, 
of patients who had similar (±20%, N = 4) or higher (>20%, 
N =  3) IL-17A levels, four of these patients also experienced 
AR, though the patient harboring the highest IL-17A levels 
of all patients (20.73  pg/ml) experienced only a grade 1 AR. 
TaBlE 7 | Relationship of cytokine and nitrate levels with severe hypotension in ANBL0931 patients.
Course 1, day 6 Course 4, day 90
Cytokine or nitrate none or ≤ gr2 
hypotension
hypotension ≥ gr3 p-Value none or ≤ gr2 hypotension hypotension ≥ gr3 p-Value
IL-5 (pg/ml) N = 42 N = 4 p = 0.018 N = 39 N = 7 p > 0.05
Mean ± SE (range) 1,043.1 ± 162.7  
(27.5–5,114.5)
148.0 ± 51.9  
(12.3–264.9)
1,224.7 ± 211.1  
(28.5–5,238.4)
1,752.0 ± 982.2 
(3.6–7,500.9)
Tumor necrosis  
factor alpha (pg/ml)
N = 61 N = 7 p > 0.05 N = 54 N = 8 p > 0.05
Mean ± SE (range) 11.8 ± 1.5 (2.5–70.6) 8.6 ± 1.4 (4.7–13.6) 19.4 ± 1.3 (5.7–54.4) 15.3 ± 2.1 (7.0–26.0)
IFNγ (pg/ml) N = 61 N = 7 p > 0.05 N = 54 N = 8 p > 0.05
Mean ± SE (range) 48.2 ± 8.2  
(1.2–317.2)
26.2 ± 9.9  
(2.2–61.0)
354.4 ± 89.7  
(0.6–2,511.0)
1,286.5 ± 1,187.9 
(3.1–9,591.9)
IL-6 (pg/ml) N = 63 N = 7 p > 0.05 N = 55 N = 8 p > 0.05
Mean ± SE (range) 31.8 ± 9.8 (1.7–618. 6) 19.1 ± 4.7 (2.5–35.5) 38.3 ± 5.1 (0.9–187.1) 26.2 ± 5.3 (1.0–54.7)
Nitrate NO3−( ) (μM) N = 81 N = 8 p = 0.04 N = 67 N = 10 p > 0.05
Mean ± SE (range) 24.2 ± 1.9 (3.5–27.8) 13.9 ± 3.0 (2.8–27.8) 28.3 ± 2.4 (5.9–102.0) 21.0 ± 2.7 (7.6–34.3)
Cytokines or nitrate during course 1 and course 4 of immunotherapy for association with clinically significant (≥grade 3) hypotension. Mann–Whitney U-test comparisons of cytokines 
were considered significant at a p-value of <0.0125 after Bonferroni correction for the four cytokines measured at each course. Nitrate levels were considered significant at p = 0.05.
FiGUrE 2 | Cytokine and nitrate levels during course 1 and 4 of immunotherapy: (a) changes in serum cytokine and nitrate levels during Immunotherapy.  
(B) Relationship between allergic reaction of any grade and serum cytokine levels on immunotherapy. Serum samples were collected before starting immunotherapy 
and just before the fourth doses of ch14.18 infusions on courses 1 (days 1 and 6) and 4 (days 80 and 90), and analyzed as described for cytokine and nitrate levels. 
Box represents 25–75% distribution, error bars represent SD, solid line is the median, dashed line is the mean. Boxes and values shown include any not-shown 
outliers unless otherwise mentioned. (a) Comparisons are by Wilcoxon signed-rank test of paired samples: day −1 versus day 6 and day 80 versus day 90.  
A p-value of < 0.0036 is considered statistically significant at level 0.05 and are Bonferroni corrected for the 14 cytokine comparisons at each course, or p < 0.05  
for nitrate. Values of outliers excluded from the graph are: d-1: IL-6 (447.4 and 416.7 pg/ml), tumor necrosis factor alpha (268.5 pg/ml), IL-4 (0.78 pg/ml), IL-12p70 
(5.48 pg/ml), IL-17A (22.4 pg/ml), IL-8 (31,818 pg/ml and also excluded from the mean, median and statistical determinations); d6: IL-6 (618 pg/ml), IL1-Ra 
(11,489.1 pg/ml), CCL22 (39,956.7 pg/ml), IL-15 (19.2 pg/ml); d80: IL-6 (862.0 pg/ml), IL-8 (2,185.5 pg/ml), IL-15 (33.7 pg/ml and 17.1 pg/ml); d90: IL-6  
(187.1 pg/ml), IL1-Ra (13,329.9 pg/ml), IFNγ (9,591.9 pg/ml), IL-10 (193.7 pg/ml), IL-4 (0.47 pg/ml), IL-5 (7,500.9 pg/ml), IL-17A (20.7 pg/ml), CXCL9 (24,172.7  
and 19,116.1 pg/ml), IL-15 (33.4 pg/ml). (B) Two-sided Mann–Whitney U-test comparison of no AR versus any AR; values are not adjusted for multiple 
comparisons. Values of outliers excluded from the graph are: d6, no AR: IL1-Ra (11,489.1 pg/ml), CCL22 (39,956.7 pg/ml), IL-15 (19.2 pg/ml); d6 AR:  
IL-6 (618 pg/ml); d90, no AR: IL1-Ra (13,329.9 pg/ml), IFNγ (9,591.9 pg/ml), IL-4 (0.47 pg/ml), IL-5 (7,500.9 pg/ml), IL-15 (33.4 pg/ml); d90 AR: IL-10  
(193.7 pg/ml), IL-17A (20.7 pg/ml), CXCL9 (24,172.7 and 19,116.1 pg/ml). Notes: IL-1Ra: interleukin-1 receptor antagonist; many CCL22 values were  
out of the range of the multiplex assay and were extrapolated. Thus, the CCL22 data and analyses should be considered qualitative.
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In contrast, IFNγ in this anaphylaxis patient (32.9 ± 0.3 pg/ml) 
was 11–16 fold lower than the average of all d90 patients, AR aver-
age and non-AR group average (474.7 ± 169.1, 365.9 ± 139.8, 
and 534.6  ±  251.5, respectively, Figure  1B; Table S2 in 
Supplementary Material), though 9 other AR patients and 14 
non-AR patients had even lower IFNγ levels.
Cytokine and nitrate Profiles and 
association With Vascular Disorders
As IL-5 levels were dramatically elevated on both courses inves-
tigated, we explored a possible relationship of this cytokine 
and the other analytes implicated with vascular disorders for 
associations with clinically significant (≥grade 3) hypotension 
(Table 7), or any grade capillary leak (Table 8). During course 1, 
hypotension was associated with lower IL-5 levels (p =  0.018), 
though, none of the associations met the required level for 
statistical significance when adjusted for the four analytes com-
pared (p < 0.0125). Nitric oxide, as measured by the more stable 
precursor nitrate, showed a small but significant decrease in 
patients with ≥ grade 3 hypotension during course 1, contrary to 
the expected association of higher nitrate levels with hypotension 
(Table 7). No association of any of the cytokines or nitrate with 
hypotension was observed during the IL-2 containing course 4.
Capillary leak incidence varied between 0 and 4% during 
different courses (Table  4). Nevertheless, in an exploratory 
fashion, we compared the cytokine and serum nitrate profile 
among patients experiencing capillary leak of grade ≥ 2 and those 
without capillary leak (Table 8). At course 1, IL-6 was the only 
cytokine of the four (TNFα, IFNγ, IL-6, IL-5) with higher levels 
in the capillary leak population (51.4 ± 27.6, N = 22), than the 
population without capillary leak (21.0 ± 2.0, N = 48, p > 0.05) 
though not statistically significant. Similarly, no statistically 
significant difference was identified for nitrate levels between 
the none vs grade ≥ 2 capillary leak subgroups. During course 4, 
average IL-5 levels were increased and IFNγ levels were decreased 
in the none vs grade ≥ 2 capillary leak subgroups, though again 
the groups were not statistically different (Table 8). In contrast to 
hypothesized high levels of cytokines, the patient who developed 
course 1 grade 3 capillary leak harbored day 6 levels of IL-5 that 
were the lowest of all patients, IL-6 the second lowest and TNFα 
ninth lowest of the entire analyzed population. On the other 
hand, serum IFNγ and nitrate levels appeared similar to the 
overall patient cohort (26th lowest of 68 patient samples for IFNγ 
TaBlE 8 | Relationship of cytokine and nitrate levels with capillary leak in ANBL0931 patients.
Course 1, day 6 Course 4, day 90
Cytokine or nitrate no capillary leaka Capillary leak ≥ gr2b p-valuec no capillary leaka Capillary leak ≥ gr2d p-valuec
IL-5 (pg/ml) N = 30 N = 16 p > 0.05 N = 25 N = 21 p > 0.05
Mean ± SE (range) 903.3 ± 133.4  
(27.5–2,787.7)
1,081.4 ± 369.4  
(12.3–5,114.5)
757.9 ± 105.8  
(3.6–2,175.8)
1,956.1 ± 450.2  
(28.5–7,500.9)
IL-6 (pg/ml) N = 48 N = 22 p > 0.05 N = 39 N = 24 p > 0.05
Mean ± SE (range) 21.0 ± 2.0 (1.7–72.6) 51.4 ± 27.6 (2.5–618.6) 34.8 ± 5.0 (1.0–124.2) 40.0 ± 8.7 (0.9–187.1)
Tumor necrosis factor  
alpha (TNFα) (pg/ml)
N = 46 N = 22 p > 0.05 N = 38 N = 24 p > 0.05
Mean ± SE (range) 9.6 ± 0.7 (2.5–23.7) 15.4 ± 0.3 (3.0–70.6) 17.6 ± 1.0 (6.0–35.7) 20.8 ± 2.6 (5.7–54.4)
IFNγ (pg/ml) N = 46 N = 22 p > 0.05 N = 60 N = 24 p > 0.05
Mean ± SE (range) 47.7 ± 10.0 (1.2–317.2) 42.2 ± 10.2 (1.4–194.8) 628.6 ± 266.5 (3.1–9,591.9) 231.0 ± 103.8 (0.6–2,459.6)
Nitrate NO3−( ) (μM) N = 65 N = 24 p > 0.05 N = 48 N = 29 p > 0.05
Mean ± SE (range) 23.2 ± 2 (2.8–106.41) 23.6 ± 3.3 (3.8–79.9) 25.8 ± 2.5 (5.9–102.0) 29.8 ± 3.8 (7.2–98.7)
aThere were no grade 1 capillary leak diagnoses.
bOne patient was diagnosed with grade 3 while the rest were grade 2. Compared to the group as a whole (see Table S2 in Supplementary Material), this patients levels of IL-5 were 
the lowest, IL-6 the second lowest and TNFα ninth lowest. IFNγ and nitrate appeared similar to the group as a whole (#26 for IFNγ and #69 for nitrate).
cTest of association of cytokine or nitrate levels with capillary leak (none versus grade ≥ 2) using a two-sided Mann–Whitney U-test at a p-value of < 0.05 without correction for 
multiple comparisons.
dTwo patients were diagnosed with grade 3 capillary leak at this time point while the rest were grade 2.
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and 69th lowest of 89 patient samples for nitrate). For the two 
patients with grade 3 capillary leak during course 4, we observed 
a cytokine expression pattern similar to that observed in the 
patient who developed capillary leak during course 1, with very 
low IL-5 (second and fifth lowest), IL-6 (fourth and eleventh 
lowest), and TNFα (sixth and thirteenth lowest). However, in 
contrast to day 6, IFNγ levels in these two patients were the lowest 
and second lowest of all patients measured. Among the 56 unique 
patients who reported Grade 2 or 3 capillary leak syndrome, 32 
patients reported in more than one course. Fourteen patients 
reported in two, 4 reported in three, 9 reported in four, and 5 
reported in five courses.
Disease Outcome
The 3-year EFS and OS rates (n =  105) were 67.6 ±  4.8 and 
79.1  ±  4.2%, respectively (Figure  3A). For the subset of 
patients > 18 months of age with INSS Stage 4 disease (n = 56), 
the 3-year EFS and OS rates were 58.9 ±  6.8 and 74.6 ±  6.0%, 
respectively (Figure 3B). There was no difference in EFS between 
patients who received ≥ 90% (n = 79; 3-year EFS: 70.3 ± 5.4%) 
vs. <90% (n = 25; 3-year EFS: 57.6 ± 10.4%) of the cumulative 
ch14.18 dose intended (log-rank p-value = 0.1486). There was no 
significant difference in the progressive disease rate between the 
lowest and highest quartiles when analyzed based on the cumu-
lative ch14.18 received per patient (chi-square p-value = 0.7306).
Cytokines and Outcome
Levels of IL-6 and other cytokines prior to initial chemotherapy 
have been associated with outcome in numerous cancers includ-
ing NB (10, 11). However, among the 15 analytes measured at 
four treatment time points in two courses of maintenance phase 
immunotherapy, only CXCL9 at day −1 showed an association 
with EFS (p =  0.05, not Bonferroni corrected, Figures  4A–B). 
No association with OS was observed nor was there any outcome 
association with changes in levels of any of the analytes including 
IL-6 during course 1 or course 4 (Figures  4C–D and data not 
shown).
DiSCUSSiOn
The immunotherapy regimen of ch14.18, GM-CSF and IL-2, 
has been shown to be efficacious in high-risk NB patients with 
minimal residual disease and is now the standard FDA-approved 
therapy (1). This confirmatory study was conducted to collect 
the additional detailed safety data required to support a BLA 
to FDA for ch14.18 (dinutuximab), which was successful. The 
nominal dose of dinutuximab (17.5  mg/m2/day) differs from 
the dose of NCI ch14.18 (25 mg/m2) because of a difference in 
the extinction coefficient used to determine the protein concentra-
tion during the manufacturing process, but despite the change 
in nominal dosing, the amount of antibody delivered per dose 
is equivalent for the two products. Marachelian et  al. reported 
a dinutuximab dose of 17.5  mg/m2 and NCI ch14.18 dose of 
25  mg/m2 producing comparable exposures, with no notable 
safety or tolerability differences in a randomized, two-sequence 
crossover study (17). Overall, this study confirmed the toxicity 
data and efficacy previously obtained in the ANBL0032 trial (1). 
Moreover, we demonstrate toxicities that are severe but manage-
able. No new or unexpected toxicities were encountered.
The side-effect profile of this immunotherapy differs greatly 
from traditional cytotoxic therapy. While the majority of 
ch14.18 related toxicities are acute, temporarily related to infusion 
of antibody, and manageable with supportive care (e.g., fever, 
neuro pathic pain); some can be life threatening and impact 
the ability to administer this therapy (e.g., anaphylaxis and/or 
bronchospasm). This study confirmed the need for close patient 
monitoring with hospitalization for administration of the 
described administration schedule to ensure timely response to 
required supportive care. Infrequently, ocular toxicities of diplo-
pia, dilated pupils or both occurred, lasting for longer duration.
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We chose to prolong the initial infusion time of ch14.18 to 
≥10 h for all patients in this study compared to the 5.75 h infusion 
on ANBL0032. There is evidence that prolongation of the infu-
sion time is associated with less toxicity. Lode et al. has reported 
decreased toxicity with continuous IV infusion of ch14.18/CHO 
(ch14.18 produced in Chinese hamster ovary cells) over 10 days 
in combination with IL-2 when compared to the same dose of 
ch14.18/CHO (100 mg/m2 as total dose) administered IV daily 
over 8  h for 5  days (18). This prolonged continuous infusion 
approach allowed a comparable dose of ch14.18/CHO to that 
used here, to be administered in the outpatient setting. Analysis 
of the safety and toxicity associated with short vs. prolonged 
(≥10 h) infusion of ch14.18 on ANBL0032 is planned and when 
combined with the results of this and other studies will help 
determine the optimal infusion duration that may mitigate toxi-
cities and potentially the cost of therapy administration.
Navid et  al. reported the results from a phase I trial using 
a novel anti-GD2 agent, hu14.18K322A, designed to decrease 
neuropathic toxicity through decreased complement binding 
(4). Kushner et  al. reported multifold dose escalation of heat 
modified 3F8 resulting in less toxicity and allowing administra-
tion in the outpatient setting (19). However, the differences 
in administration schedule, cytokine use and toxicity grading 
impair our ability to directly compare toxicity rates across these 
clinical trials (20).
The pharmacokinetics of ch14.18 in children with NB was 
previously characterized by intra- and inter-patient variability 
(21). Desai et al. studied detailed pharmacokinetics of ch14.18 
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in 14 pediatric subjects who received identical immunother-
apy as delivered on ANBL0931 and demonstrated less variable 
ch14.18 disposition than previously reported (13). In compa-
rison, pharmacokinetics profiles obtained through a very limi-
ted sampling on ANBL0931 demonstrated lower mean peak 
ch14.18 concentrations (5.5 vs 11  mcg/ml) but higher mean 
trough concentrations (0.78 vs 0.2  mcg/ml) than reported by 
Desai. This difference could be a function of limited sampling 
in both studies. Similar to prior experience with ch14.18 when 
administered following ASCT in patients with NB (1), the 
development of HACA was uncommon. No dose modification 
was done based on HACA results in our patients.
Cytokines can orchestrate inflammation and immunity 
and can be key players in toxicity reactions such as AR in 
general, and anaphylaxis in particular. The course-associated 
average increases in cytokine levels reflected individual increa-
ses in the vast majority of patients despite a large range of 
variation. These increases may be due to the administration of 
cytokines GM-CSF and IL-2 during therapy, due to ch14.18, or 
both. However, cytokine levels of the patients experiencing AR 
appeared similar to those of patients who did not experience 
AR. IL-5 exhibited the largest course-associated fold-increase in 
patients vs. normal controls, as much as 20,000-fold higher and 
is reported to promote IgE and eosinophilic responses (22), while 
IL-5 did have an association with hypotension, it did not have an 
association with AR in patients on immunotherapy.
Cytokines can also promote tumor cell growth, migration, and 
metastasis or create an immunosuppressive microenvironment 
FiGUrE 4 | CXCL9 and IL-6 versus survival in immunotherapy treated patients. CXCL9 (a,B) and IL-6 (C,D) were measured in the serum of ANBL0931 patient 
samples obtained at pretreatment to course 1. Patient values were sorted as to above or below median levels of all patients and a Kaplan Meier survival analysis  
for event-free survival (a,C) and OS (B,D) assessed and significance assessed by Log Rank test.
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(23). CXCL9 is a T- and NK-cell chemoattractant that displays 
antitumor and pro-tumor activities. Consistent with this 
observation, high levels of serum CL1 chemokine cluster, which 
includes CXCL9, was correlated with an shorter OS in chronic 
lymphocytic leukemia (11), suggesting that high levels of CXCL9 
and related chemokines might predict a poor prognosis in NB 
as well.
IL-6 has also been reported to be part of a multi-protein 
biomarkers signature in a retrospective study to be associated 
with relapse in high risk NB (24). In this study, there was no 
association of IL-6 with event or outcome before and during 
maintenance phase immunotherapy plus cytokines. However, 
we must caution about possible variable time between blood and 
plasma isolation in the reported retrospective study (24), know-
ing that handling of sample can greatly affect measured levels 
of cytokines (25, 26), and our own data demonstrating highly 
variable and often unreliable cytokine values when measured in 
plasma (unpublished observations). Thus, while IL-6 levels may 
be able to predict outcome for some types of chemotherapy when 
measured at diagnosis, or retrospectively predict relapse, its level 
at the start of maintenance phase with ch14.18 immunotherapy 
is not prognostic of outcome.
The induction of nitric oxide as a consequence of IL-2 admin-
istration is thought to be responsible for immunotherapy-asso-
ciated capillary leak syndrome and hypotension (7, 8). However, 
nitric oxide levels, as determined through the measurement of 
the more stable metabolite nitrate, were slightly but significantly 
decreased in a paired samples analysis during both GM-CSF 
and IL-2 courses of therapy, and were paradoxically associated 
with severe hypotension in the non-IL-2 containing course 1. 
In the single patient who developed course 1 severe capillary 
leak, nitrate levels were similar to those of the group as a whole. 
These data suggest that the cause of immunotherapy-associated 
vascular disorders is not due to nitrate release. However, given 
the known role of nitric oxide in vascular relaxation, it is hard to 
understand the decrease in nitrate levels during immunotherapy, 
or why lower levels might be associated with hypotension, though 
it may be as simple as timing of the blood sample draw versus the 
observation of toxicity.
Several cytokines showed associations with the occurrence of 
hypotension and capillary leak. However, as with nitrate, lower 
levels of some cytokines were associated with vascular disorders. 
In particular, the capillary leak patients had some of the lowest 
cytokine levels of all samples analyzed. Considering the dramatic 
increase in cytokines we have observed during the course of 
therapy and the reported relationships of elevated TNFα and IL-6 
with vascular permeability (27), this is a paradoxical observation. 
One might speculate that the increase in cytokines we observed 
during therapy may be a protective response that helps maintain 
vascular integrity. In patients with low cytokine levels, this 
protective response may be compromised and be reflected in the 
observed vascular disorders. Thus, when compared to patients 
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